金融界消息 截至2025年8月5日收盘，中恒集团（600252）报收于3.01元，上涨9.85%，换手率1.46%， 成交量48.23万手，成交金额1.45亿元。 资金流向方面，今日主力资金净流入6998.27万元，占比成交额48.21%。其中，超大单净流入8960.37万 元、占成交额61.73%，大单净流出1962.10万元、占成交额13.52%，中单净流出流出3381.31万元、占成 交额23.29%，小单净流出3616.96万元、占成交额24.92%。 天眼查商业履历信息显示，广西梧州中恒集团股份有限公司，成立于1993年，位于梧州市，是一家以从 事医药制造业为主的企业。企业注册资本345148.9454万人民币，实缴资本5744万人民币。公司法定代 表人为杨金海。 通过天眼查大数据分析，广西梧州中恒集团股份有限公司共对外投资了32家企业，参与招投标项目103 次，知识产权方面有商标信息5条，此外企业还拥有行政许可14个。 来源：金融界 中恒集团最新一期业绩显示，截至2025一季报，公司营业总收入7.42亿元、同比减少7.92%，归属净利 润1826.71万元，同比减少66.61%，扣非净利润1577 ...

Market Overview - The Shanghai Composite Index closed at 3602.13 points, above the five-day moving average, with a gain of 0.53% [1] - The total trading volume of A-shares reached 10185.93 billion yuan [1] Stocks Performance - A total of 1060 A-shares have prices that surpassed the five-day moving average [1] - Notable stocks with significant deviation rates include: - Nanjing Julong (11.66%) - Dongxin He Ping (7.92%) - Zhongheng Group (7.73%) [1] Top Stocks by Deviation Rate - The following stocks had the highest deviation rates from the five-day moving average: - Nanjing Julong: 13.63% increase, trading volume 21.00% [1] - Dongxin He Ping: 10.00% increase, trading volume 20.47% [1] - Zhongheng Group: 9.85% increase, trading volume 1.31% [1] - Jianlong Micro-Nano: 9.14% increase, trading volume 3.44% [1] - San Chao New Materials: 9.88% increase, trading volume 26.05% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Boshang Optoelectronics: 10.52% increase, trading volume 25.60% [1] - Astone Creation: 11.98% increase, trading volume 28.04% [1] - Shanghai Shifa Development: 10.06% increase, trading volume 2.46% [1] - Fuheng New Materials: 7.19% increase, trading volume 11.34% [1] - Dazhu Digital Control: 8.32% increase, trading volume 17.89% [1]

Group 1 - As of August 4, 2025, Zhongheng Group's stock price is 2.74 yuan, down 0.02 yuan or 0.72% from the previous trading day [1] - The trading volume for the day was 616,400 hands, with a total transaction amount of 166.7 million yuan [1] - Zhongheng Group primarily engages in pharmaceutical manufacturing, with core products including thrombolytic agents for cardiovascular diseases [1] Group 2 - The company has a wholly-owned subsidiary, Zhongheng Innovation, which acquired a patent for a drug treating chronic heart failure for 55 million yuan [1] - This drug is a novel compound discovered by the Navy Medical University, significantly enhancing myocardial energy metabolism, and currently, there are no similar drugs on the market globally [1] - The company operates in various sectors, including pharmaceutical manufacturing, research and development, and health food, making it a key player in the Guangxi region [1]

Summary of Key Points Core Viewpoint - Guangxi Wuzhou Zhongheng Group Co., Ltd. has acquired a patent for a drug technology aimed at treating chronic heart failure through its wholly-owned subsidiary, Zhongheng Innovation, for a total price of RMB 55 million [1][2][3]. Transaction Overview - The acquisition involves a drug technology (patent) for treating chronic heart failure, with the transaction price set at RMB 55 million, excluding tax [1][3]. - The transaction has been approved by the company's board of directors and does not require shareholder approval [1][3]. - The contract was signed on August 1, 2025, following the receipt of qualification confirmation from the Shanghai Technology Exchange [2][3]. Transaction Details - The project was publicly listed for transfer on May 20, 2025, with a minimum bid price of RMB 55 million and a deposit of RMB 500,000 [3]. - Payment for the transfer will be made in stages, with an initial payment of at least RMB 5 million due within 10 working days after the contract takes effect [3][6]. Drug Technology Information - The drug, referred to as LZ-01, is a novel compound discovered by the Navy Medical University of the People's Liberation Army, which significantly improves myocardial energy metabolism and heart function in chronic heart failure patients [5][6]. - The drug is classified as a Class 1 innovative chemical drug, administered orally, and is currently in the preclinical research phase [6]. Impact on the Company - This acquisition aligns with the company's strategic focus on unmet clinical needs and potential markets, particularly in cardiovascular and metabolic diseases [8]. - The transaction is expected to enhance the company's product line and market competitiveness without significantly impacting its short-term financial performance [8].

Core Viewpoint - Zhongheng Group's subsidiary, Guangxi Zhongheng Innovative Pharmaceutical Research Co., Ltd., has acquired a patent for a drug (LZ-01) that treats chronic heart failure, enhancing the company's product line and market competitiveness [1] Group 1: Acquisition Details - The acquisition price for the drug technology is 55 million yuan (excluding tax) [1] - The drug LZ-01 was initially discovered by the Navy Medical University of the People's Liberation Army and is noted for significantly improving myocardial energy metabolism and heart function in chronic heart failure patients [1] Group 2: Strategic Implications - The acquisition aligns with Zhongheng Group's strategic planning and is expected to expand the company's business and enhance its market competitiveness [1] - LZ-01 is characterized by good drug properties and oral administration, with no similar products available domestically or internationally, providing a significant therapeutic advantage for patients with reduced ejection fraction chronic heart failure [1]

Core Viewpoint - Zhongheng Group (600252.SH) is acquiring a patented technology for treating chronic heart failure from the Navy Medical University of the People's Liberation Army, aligning with its strategic development goals [1] Summary by Relevant Sections Acquisition Details - Zhongheng Innovation, a wholly-owned subsidiary of Zhongheng Group, plans to acquire the patent for a drug technology aimed at treating chronic heart failure [1] - The project has a base transfer price of RMB 55 million, with a deposit of RMB 500,000 required [1] - The transfer process includes an initial payment of at least RMB 5 million, due within 10 working days after the contract takes effect, followed by milestone payments upon the occurrence of specified events [1] Timeline and Confirmation - The transfer listing will end on June 18, 2025, with the confirmation of Zhongheng Innovation as the acquirer occurring on June 20, 2025 [1] - A formal contract for the technology transfer was signed between Zhongheng Innovation and the China Runtong Research Institute on August 1, 2025 [1]

广西梧州中恒集团股份有限公司 关于全资子公司受让取得一种治疗慢性心力衰竭的 药物技术（专利权）并签署《技术（专利权）转让 合同》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600252 证券简称：中恒集团 公告编号：临 2025-72 ● 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）的 全资子公司广西中恒创新医药研究有限公司（以下简称"中恒创新"）以受让方 式取得中国融通科学研究院集团有限公司（以下简称"中国融通科研院"）在上 海技术交易所公开挂牌转让的一种治疗慢性心力衰竭的药物技术（专利权），交 易价格为人民币 5,500.00 万元（不含税，下同）。 2025 年 6 月 20 日，中恒创新收到上海技术交易所出具的《受让资格确认通 知书》《组织签约通知》，确认中恒创新为"一种治疗慢性心力衰竭的药物"的 受让方。成交价格为人民币 5,500.00 万元。 ● 本次交易不构成关联交易，也不构成重大资产重组。 ● 本次交易已经公司第十届董事会第二十九次会议审议通过，无需提交 ...

每经AI快讯，8月4日，中恒集团（600252）公告称，公司全资子公司中恒创新以5500万元受让中国融 通科研院在上海技术交易所公开挂牌转让的一种治疗慢性心力衰竭的药物技术(专利权)。中恒创新将分 期支付转让价款，并需完成临床前药代动力学研究等工作。药品研发存在诸多不确定性，包括临床试验 进度及结果、未来产品市场竞争形势等。 ...

人民财讯8月4日电，中恒集团（600252）8月4日晚间公告，公司全资子公司广西中恒创新医药研究有限 公司(以下简称"中恒创新")以受让方式取得中国融通科学研究院集团有限公司(简称"中国融通科研院") 在上海技术交易所公开挂牌转让的一种治疗慢性心力衰竭的药物技术(专利权)，交易价格为5500.00万元 (不含税)。 ...

Group 1 - The company provided a guarantee for its subsidiary, Shuangqian Industry, to support its daily operations and business development needs, with a maximum guarantee amount of RMB 19 million [1][4] - The guarantee was approved during the company's board meeting and annual shareholders' meeting, allowing for a total credit limit of up to RMB 5 billion for 2025, with a maximum guarantee amount of RMB 2.5 billion [2][5] - The company has a total external guarantee balance of RMB 401.82 million, which is 6.67% of its audited net assets for 2024, with no overdue guarantees reported [7] Group 2 - The company initiated a share repurchase plan, allowing for the buyback of shares at a price not exceeding RMB 3.80 per share, with a total repurchase amount between RMB 300 million and RMB 500 million [11] - As of July 31, 2025, the company had repurchased a total of 109.86 million shares, representing 3.32% of its total share capital, with a total payment of approximately RMB 277.30 million [12] - The company will continue to comply with relevant regulations and disclose progress on the share repurchase in a timely manner [13]